Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14186 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Anke Gerhardt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Schwerpunktpraxis für Hämatologie und Onkologie Potsdam, Potsdam, Germany. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Adenine, Piperidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen-Cilag GmbH.
Abstract (Originalsprache)
Objectives
To assess treatment adherence, effectiveness and safety outcomes of patients with chronic lymphocytic leukaemia (CLL) receiving ibrutinib in a real‐world setting.
Methods
Patients enrolled in REALITY were ≥18 years with a confirmed diagnosis of CLL and were receiving ibrutinib as a first‐line (1L), 2L or ≥3L therapy. Treatment retention, adherence, progression‐free survival (PFS), overall survival (OS) and time to next therapy were assessed at 1 and 2 years overall, by typology and by cytogenetic subgroups. PFS and OS were analysed using Kaplan–Meier methods.
Results
Exactly 302 patients were enrolled across 57 sites in Germany, from January 2017 to July 2021. One‐year retention rates were 69.9% overall (primary endpoint), 77.9% for 1L patients, and 77.6%/78.8% for high‐risk patients with del17p/ TP53 . At 2 years, PFS/OS rates were 77.8%/90.7% overall (1L, 82.7%/90.4%), and were consistent across cytogenetic subgroups. PFS rates were higher for 1L versus ≥3L patients. Patients with the low‐acceptance/low‐control typology at baseline were less likely to retain treatment at 1 year versus the high‐acceptance/high‐control typology. No new safety signals were observed.
Conclusions
The REALITY study provides further evidence of the effectiveness and safety of ibrutinib in patients with CLL in a real‐world setting, particularly in earlier treatment lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Schwerpunktpraxis für Hämatologie und Onkologie Potsdam, Potsdam, Germany.
- Onkozentrum Dresden, Dresden, Germany.
- Praxis Internistischer Onkologie und Hämatologie, Frechen, Germany.
- Hämatologisch-Onkologische Schwerpunktpraxis Würzburg, Würzburg, Germany.
- Janssen-Cilag GmbH, Neuss, Germany.
- MVZ am Klinikum Aschaffenburg, Aschaffenburg, Germany.
Förderung
- Janssen-Cilag GmbH
Zitieren
APA
Gerhardt, A., Dörfel, S., Schulz, H., Schlag, R., Vornholz, L., Nejad-Asgari, S., & Welslau, M. (2024). Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study. European Journal of Haematology. https://doi.org/10.1111/ejh.14186
Vancouver
Gerhardt A, Dörfel S, Schulz H, Schlag R, Vornholz L, Nejad-Asgari S, et al. Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study. European Journal of Haematology. 2024. doi:10.1111/ejh.14186
BibTeX
@article{Gerhardt2024,
author = {Gerhardt, Anke and Dörfel, Steffen and Schulz, Holger and Schlag, Rudolf and Vornholz, Lukas and Nejad-Asgari, Sonja and Welslau, Manfred},
title = {Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14186}
}
EUVIMED